变构调节
代谢型谷氨酸受体
代谢型谷氨酸受体2
代谢型谷氨酸受体1
代谢型谷氨酸受体5
代谢型谷氨酸受体7
药物发现
C级GPCR
变构调节剂
代谢受体
药理学
代谢型谷氨酸受体6
G蛋白偶联受体
生物
谷氨酸受体
受体
化学
神经科学
生物化学
作者
K.A. Bennett,J.A. Christopher,Benjamin G. Tehan
出处
期刊:Advances in pharmacology
日期:2020-01-01
卷期号:: 35-58
被引量:6
标识
DOI:10.1016/bs.apha.2020.03.001
摘要
The metabotropic glutamate (mGlu) receptors are a family of eight class C G protein-coupled receptors (GPCRs) which modulate cell signaling and synaptic transmission to the major excitatory neurotransmitter l-glutamate (l-glutamic acid). Due to their role in modulating glutamate response, their widespread distribution in the central nervous system (CNS) and some evidence of dysregulation in disease, the mGlu receptors have become attractive pharmacological targets. As the orthosteric (glutamate) binding site is highly conserved across the eight mGlu receptors, it is difficult not only to generate ligands with subtype selectivity but, due to the nature of the binding site, with suitable drug-like properties to allow oral bioavailability and CNS penetration. Selective pharmacological targeting of a single receptor subtype can be achieved by targeting alternative (allosteric) binding sites. The nature of the allosteric binding pockets allows ligands to be developed that have good physical chemical properties as evidenced by several allosteric modulators of mGlu receptors entering clinical trials. The first negative allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor were discovered from high throughput screening activities. An alternative approach to drug discovery is to use structural knowledge to enable structure-based drug design (SBDD), which allows the design of molecules in a more rational, rather than empirical, fashion. Here we will describe the process of SBDD in the discovery of the mGlu5 negative allosteric modulator HTL0014242 and describe how knowledge of receptor structure can also be used to gain insights into the receptor activation mechanisms.
科研通智能强力驱动
Strongly Powered by AbleSci AI